Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adefovir Dipivoxil in HIV/HBV/HCV Coinfection
NCT00051077Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in hepatitis B (HBV) comparing Adefovir Group with Placebo Group (2 arms). Primary endpoints: Safety and tolerability at 48 weeks and Anti-HBV Efficacy at 48 weeks. Status: withdrawn.
02
Drugs
adefovir dipivoxil
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00051077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051077.